Take a look at HEMISPHERX BIOPHARMA (AMEX: HEB) In at 1.14

[DeathEatsaCracker]

If it's going to pop, I hope this is the time so I can put some of the profits in CTIC, because that one could be next.

 

[Willie99]

PHILADELPHIA, July 20, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) will provide an update on its Influenza research initiatives via teleconference on Wednesday, July 22, 2009, at 10:00 AM EDT. Initiatives to be discussed will include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Background information may be sourced at Wall Street Journal, July 18/19, 2009, p. A3.
---------------------------------------------------------------

so after sitting around $ 2 for the last month, the stock is up to 2.42 (+31) at the time of this post

we may have a 48 hr run until the news is released. after that, who knows

closed @ 3.31, ending a two day run at + 1.20 and + .89 or 37% since I made this post.

now we'll find out if it stands this time

@)

 

[DeathEatsaCracker]

I'd like to know who is buying. The announcement seems rather innocuous.

 

[DeathEatsaCracker]

Why am I not surprised?

 

[Willie99]

tank city baby, 2.40 down .91

obviously traders wanted something more than this

-----------------------------------------------------------------------


Hemispherx BioPharma (AMEX: HEB) 28% LOWER; sinking today amid the company's conference call to discuss recent Influenze research initiatives. Hemispherx said it is targeting 25-50 million doses of Ampligen per year, as well as at least 100 million doses of Alferon LDO at capacity, two initiatives which are expected to cost the company about $10 million.

------------------------------------------------------------------------

I'm gonna have to start buying when a news conference is announced and selling before the actual news conference

two big swings in two months

 

[ScottL]

I don't know if you guys would be interested but here's a good blog on Pharmacy stocks:

http://www.cnbc.com/id/15837675/

 

[DeathEatsaCracker]

Well this stock is pretty much dead until this fall. After Adam Feuerstein's next article it'll probably drop below $2.